MSLN and mesothelioma: In contrast, MSLN is highly expressed in human cancers including 70% of ovarian cancers [54,64,65,66], mesotheliomas [54], and pancreatic adenocarcinoma [67,68] and therefore identified as a tumor-associated marker.